MEDIAN Technologies names Ciaran Cooper as Head of Business Development, Clinical Trials Imaging, North America
MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer, and a service provider for image interpretation and management in oncology clinical trials, announced today that it has named Ciaran Cooper as Head of Business Development, Clinical Trials Imaging, North America. Ciaran Cooper will be responsible for developing the company’s US market in oncology clinical trials and will assist in managing the strategic relationship between MEDIAN Technologies and Quintiles.
Ciaran Cooper, an entrepreneur and early innovator in the clinical trials imaging services industry, brings over 20 years’ experience in medical imaging with an emphasis in business development, strategic planning, and team management. Along with colleagues from the University of Chicago, Ciaran Cooper co-founded MIICRO, Inc. in 1995, the first imaging CRO specialized in early phase translational imaging with FDG PET. He was CEO of MIICRO until 2003. Since then, Ciaran Cooper has worked for several imaging services and technology companies as a senior manager in business development and thus brings with him a vast knowledge of various business models, therapeutic areas, and growth strategies.
“I’m very excited to join MEDIAN at this time in their development,” said Ciaran Cooper. “MEDIAN’s LMS solution provides a quantum leap forward in how medical imaging can be applied to oncology clinical trials. I look forward to carrying our message to market.”
“We’re thrilled to welcome Ciaran to our team,” said Jerome Windsor, VP Business Development at MEDIAN Technologies. “Ciaran has a unique perspective on the industry and he brings an entrepreneurial spirit and enthusiasm that will fit well with our growing company.”
About Median Technologies.
Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.
Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.
“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”